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Background: Diabetic retinopathy, the main microvascular complications of diabetes and one of the leading
causes of blindness worldwide. Interesting reports on the role of inflammatory/proangiogenic high mobility group
1 (HMGB-1) cytokine and phospholipases A2 (PLA2) in neovascularization have diverted our concentration to reveal
whether HMGB-1 and PLA2 plays role in diabetic retinopathy.
Methods: We performed our study in streptozotocin (STZ)-induced diabetic rat model. The expression levels of the
cytokines, chemokines, and cell adhesion molecules in retinal tissues were evaluated by quantitative RT-PCR.
HMGB-1 and PLA2 protein levels along with VEGF, TNF-α, IL-1β and ICAM-1 levels were also measured.
Results: We observed the retinal pericytes, endothelial injury/death and breakdown of blood–retinal barrier (BRB).
The protein expression of HMGB-1, PLA2 and IL-1β were significantly increased in micro vessels from retina of
diabetic rats. Diabetic rats had also high retinal levels of VEGF, ICAM-1 and TNF-α. Further investigation revealed that
pericyte death is mediated by HMGB-1-induced cytotoxic activity of glial cells, while HMGB-1 can directly mediate
endothelial cell death. Similarly, increased expression of PLA2 represents the diabetic mediated alteration of BRB,
perhaps up regulating the VEGF.
Conclusions: Our data suggest that HMGB-1 and PLA2 involved in retinal pericyte and endothelial injury and cell
death in diabetic retinopathy. From this study, we suggest that HMGB-1 and PLA2 may be interesting targets in
managing diabetic retinopathy.
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Diabetic retinopathy is the most common micro-vascular
complication of diabetes and remains one of the leading
causes of blindness in adults [1]. As a global concern,
diabetes affects more than 360 million individuals world-
wide. This number is expected to exceed half a billion by
2030 [2]. About one in three individuals with diabetes has
signs of retinopathy, with in these, one-third may have
diabetic macular edema (DME) or proliferative diabetic
retinopathy (PDR), two vision-threatening forms of* Correspondence: zhangmaonian80@gmail.com
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unless otherwise stated.diabetic retinopathy [3]. Diabetic retinopathy is a progres-
sive alteration in the retinal microvasculature, leading to
areas of retinal non-perfusion, increased vasopermeability,
and pathologic intraocular proliferation of retinal vessels
in response to retinal nonperfusion. Due to progressive
retinal capillary dropout, the ischemic retina mounts an
angiogenic response leading to a more advanced form of
the disease, proliferative diabetic retinopathy [1]. However,
the mechanism behind was not clear.
HMGB-1 protein is a nuclear DNA binding protein re-
leased passively from necrotic cells as well as actively from
monocytes/macrophages and endothelial cells. HMGB-1
can activate the pattern recognition receptors toll-like
receptor 4 (TLR4) and receptor for advanced glycation end
products (RAGE), triggering inflammation and damage astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gong et al. Lipids in Health and Disease 2014, 13:156 Page 2 of 8
http://www.lipidworld.com/content/13/1/156well as promoting angiogenesis in tissue [4,5]. Studies have
reported that noxious stimuli such as amyloid beta induce
activation of cytosolic PLA2 in bovine pericytes [6,7] and,
recent study shown have that cytosolic PLA2 activation is
required for hypoxia-induced VEGF-dependent retinal
neovascularization [8].
Numerous biochemical changes have been observed in
the vascular tissue of the retina, which are believed to be
involved in diabetic retinopathy. A major change con-
siders the signaling of vascular endothelial growth factor
(VEGF), the crucial regulator of vasculogenesis, angio-
genesis, lymphangiogenesis and vascular permeability
in vertebrates [9]. There is also increasing evidence
that inflammation has a key role in the pathogenesis of
diabetic retinopathy, which is characterized by early
breakdown of BRB and loss of pericytes/endothelial
cells, which are essential for retinal capillary structure
and function [3,10]. Vascular adhesion molecules such
as intercellular adhesion molecule-1 (ICAM-1) and
cytokines such as TNF-α, among many others, have
been implicated in the pathogenesis of DR [11]. VEGF
increases retinal vascular expression of ICAM-1 [11],
and this latter is directly involved in inflammation through
its interaction with different cytokines such as TNF-α
[12]. Based on the previous reports, our present study is
aimed to reveal the possible mechanism of HMGB-1 and
PLA2 on their involvement in diabetic retinopathy. The




All chemicals and reagents were purchased from Sigma-
Aldrich (St. Louis, MO), Life Technologies (Grand Island,
NY), and Thermo Scientific (Rockford, IL), unless other-
wise indicated. Recombinant HMGB-1 was purchased from
R&D Systems (Minneapolis, MN) and IBL International
Corp (Toronto, ON). Rabbit polyclonal antibody against
von Willebrand factor, mouse monoclonal antibodies
against cPLA2, α-actin and GAPDH were purchased from
Santa Cruz (Santa Cruz, CA). Streptozotocin (STZ) was
purchased from Sigma. All the other reagents were ob-
tained from standard commercial suppliers unless other-
wise noted.
Experimental animals
Male Sprague–Dawley rats weighing approximately 200 g
were used for the experiment. All the animals were treated
according to the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Oph-
thalmic and Vision Research. Animals were housed under
standard conditions of temperature and humidity, with a
12 hour light/dark cycle and free access to food and water.
After 12 h of fasting, the animals received a single 60 mg/kgintravenous (i.v.) injection of STZ in 10 mM sodium cit-
rate buffer, pH 4.5 (1 ml/kg dose volume). Control (non-
diabetic) animals were fasted and received citrate buffer
alone. After 24 h, animals with blood glucose levels >
250 mg/dl were considered diabetic, and randomly divided
in groups of ten animals each. The diabetic state was
confirmed by evaluating glycemia daily through a blood
glucose meter (Accu-Check Active1, Roche Diagnostic,
Milan, Italy). Body weight was assessed daily. AACOCF3
was dissolved in saline and injected intravitreally (ITV;
2 ml) at 0.1, 1, 10 and 50 mM. All the experiments were
performed 15 days following the induction of diabetes.
Cell cultures
Primary microvascular endothelial cells from bovine retinas
(BREC) were purchased from European Collection of Cell
Cultures (ECACC) and were fed with Ham’s F-10 medium
as previously described [13]. Primary microvascular peri-
cytes (BRPC) were isolated from bovine retina microvessels
as previously described [14]. The isolated cells were then
cultured in DMEM supplemented with 10% Fetal Bovine
Serum, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Morphological changes and cell viability was determined by
MTT test.
TUNEL assay
The terminal deoxynucleotidyl transferase-mediated bio-
tinylated UTP nick end labeling (TUNEL) reaction was
done along with DAPI staining. The protocol was adapted
from Gavrieli et al. [15]. The prepared tissue sections were
deparaffinized in xylene for 10 min and hydrated through a
graded ethanol series. The TUNEL assay was then carried
out according to the manufacturer’s (Roche Diagnostics,
Meylan, France) instructions; the samples were stained with
DAPI solution after the TUNEL reaction.
Evaluation of protein expression
Rat eyes were collected two weeks after STZ administra-
tion, and each retina was processed as previously described
[16]. Briefly, the retina was homogenized in 100 ml of solu-
tion containing (mM): imidazole hydrochloride, 20; KCl,
100; MgCl, 1; EGTA, 1; NaF, 10; sodium molybdinate, 1;
EDTA, 1; plus 1% Triton. The solution was supplemented
with a cocktail of protease inhibitors (Complete Protease
Inhibitor Cocktail; Roche, Basel, Switzerland) before use.
The soluble proteins, 10–20 μg, were loaded and separated
by 10% SDS–PAGE and blotted onto a polyvinylidene
fluoride membrane. Then, the membranes were blocked
with 5% nonfat dry milk powder solution for 1 h at room
temperature before an overnight incubation with primary
antibodies TNF-α, VEGF, IL-1β and ICAM-1 (Santa Cruz
Biotech.) at 4°C. After rinsing the membranes, they were
incubated with secondary antibody for 1 h at room
temperature and the bands were made more visible by
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[17]. The intensity of each band was normalized to that
of β-actin and quantified using the Image J analysis.
Gene expression analysis
Quantitative RT-PCR was performed to analysis the
gene expression status by using gene-specific primers
(Table 1). Specifically, RNA was extracted from retinal
cells using RNA Nanoprep kit (Agilent Technologies,
Santa Clara, CA), and reverse transcribed with the
Reverse Transcription System (Promega, Madison, WI) to
synthesize cDNA. Quantitative PCR was performed in the
Rotor-Gene Q Cycler (Qiagen, Valencia, CA) using the
SYBR GREEN PCR Master Mix (Qiagen, Valencia, CA).
For each gene, relative expression was calculated by com-
parison with a standard curve, following normalization to
the housekeeping gene β-actin expression chosen as a
control.
Statistical analysis
Statistical significance between two groups was analyzed by
Student’s t-test. One-way analysis of variance (ANOVA),
followed by Tukey’s post hoc test, was used to compare the
means for the multiple groups. The p value < 0.05 was
considered statistically significant.
Results
Changes observed at the end of experiments
The diabetes was induced after twelve weeks of STZ injec-
tion; we found a significant (p < 0.05) difference between
the normal and diabetic rats in body weight, eyeball weight,
and serum glucose levels. The intakes of water and food
were markedly increased in the diabetic rats (Table 2).
Apoptosis in the retinal ganglion cell layer in STZ-induced
diabetic rats
To identify apoptotic cell death in the retina affected by
diabetes, whole retinas were reacted with TUNEL. The
TUNEL positive cells were stained with green, DAPI
with blue and the merged image shows the combin-
ation of green and blue (Figure 1). Twelve weeks after
the induction of diabetes, TUNEL-positive cells were
observed in the ganglion cell layer, and a large number
of apoptotic ganglion cells were present in the retinas
of STZ-induced diabetic rats (Figure 1).Table 1 List of RT-PCR primers
Gene Forward
β-Actin 5′-CGT AAA GAC CTC TAT GCC AA-3′
TNF-α 5′-CAA AAT TCG AGT GAC AAG CCT G-3′
VEGF 5′-AAC CAT GAA CTT TCT GCT CTC TTG-3
ICAM-1 5′-CCC TGT CAG TCC GGA AAT AA-3′
PLA2 5′-CAG CAA GGA UCC UCG CUA U-3′Evaluation of mRNA levels in retinal tissue
The mRNA levels of the cytokines, chemokines, and cell
adhesion molecules in retinal tissues were evaluated by
quantitative RT-PCR. The samples from diabetic retinop-
athy (DR) and their respective control were observed. The
mRNA levels of HMGB1 and PLA2 were found a signifi-
cant (4.5 fold) increase in DR tissue (Figure 2). Similarly,
TNF-α, VEGF and ICAM-1 were increased at least to 2.5
fold in DR when compared to that of control tissue.Evaluation of protein levels in retinal tissue
The protein levels were detected and quantified by using
western blot analysis in retinal tissues of DR and their
respective control. Interestingly, similar to the results
obtained in the gene expression study. We observed sig-
nificantly elevated level of HMGB1 and PLA2 in DR tissue
than that of normal tissue (Figure 3). The protein levels of
IL-1β, TNF-α, VEGF and ICAM-1 were found similar
elevation in DR tissue when compared to the control
tissue. The corresponding band intensity was plotted in
bar graph (Figure 3). Interestingly, HMGB1 was more
prominently found among others proteins evaluated in
both gene expression as well as protein study.Evaluation of PLA2 activity in microvessels of retina from
control and diabetic rats
PLA2 activity was strongly increased in microvessels from
DR rats for about 3 fold when compared to control rats
(Table 3). Treatment with AACOCF3 (ITV, 2 ml, 50 mM)
reduced PLA2 activity down to the level of control rats.
The western blot analysis was performed to evaluate
the expression of cPLA2 and its phosphorylated form
(p-cPLA2), iPLA2, COX-1 and COX-2 in microvessel
lysates obtained from retina of experimental rats
(Figure 4). An increased expression of cPLA2 was found
in microvessels from retina of diabetic rats (Figure 4). The
phosphorylated form of cPLA2 was further increased
(about 9.5 fold) in diabetic rats and its expression did not
change after treatment with AACOCF3. Moreover, iPLA2
expression was increased for about 2.6 fold in diabetic
rats and, as expected, its expression did not change
after treatment with AACOCF3. These results are
consistent with in vitro findings (data not shown)
showing in endothelial cells a contribution of bothReverse
5′-AGC CAT GCC AAA TGT GTC AT-3′
5′-GAG ATC CAT GCC GTT GGC-3′
′ 5′-GCC TGG CTC ACC GCCTTG GCT TGT C-3′
5′-GAT GAC TTT TGA GGG GGA CA-3′
5′-CAG AAU GCU UCC AAU CGU A-3′
Table 2 Basic Parameters measured at the end of experiment
Parameters Normal (n=12) STZ-induced diabetic rats (n=12)
Body weight (g) 425.1 ± 4.9 214.4 ± 11.4
Eyeball weight (mg/100 g B.W) 39.8 ± 4.5 74.3 ± 12.9
Serum glucose (mg/dL) 135.13 ± 3.12 540.02 ± 37.51
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after the induction of diabetes.
Immunohistochemistry of retinal tissue for HMGB1
staining
The immunohistochemical study was performed to deter-
mine the presence of HMGB1 and to quantify the staining
intensity in retinal tissues of DR and their respective con-
trol. The HMGB1 stained with red, the DAPI stained with
blue color and the merged image was also presented with
the combination of red and blue (Figure 5). The abundant
HMGB1 expression was observed in DR tissues when
compared to the control tissue. This result indicates the
significant involvement of HMGB1 in DR.
Discussion
Diabetic retinopathy is one of the major microvascular
complications of diabetes and one of the most commonFigure 1 Apoptosis detected in retinal cell by TUNEL and DAPI stainin
retinal layer of STZ-induced diabetic retinopathy rats. The apoptotic retinal
(blue) were stained with DAPI. Scale bar = 50 μm.causes of blindness among elderly people [1,18]. During
diabetes the retinal microvessel cells are subjected to the
action of prolonged hyperglycemia, and undergo progres-
sive dysfunction leading to neovascularization (NV) and
vascular leakage [19]. The histopathology of diabetic retin-
opathy include loss of blood-vessel pericytes and endothe-
lial cells, and abnormal new blood vessel growth on the
surface of the retina in the more advanced stage of the
disease, proliferative diabetic retinopathy [1,18]. Recent re-
ports have elucidated that HMGB-1 is involved in the
pathogenesis of diabetic microvascular complications,
including diabetic retinopathy [20,21]. However, cellular
mechanisms of HMGB-1 action in the diabetic retina re-
main incompletely understood. HMGB-1, a DNA-binding
nuclear protein can be released actively after cytokine
stimulation and passively during necrotic cell death [4].
HMGB-1 can promote inflammatory responses and cause
damage by numerous mechanisms [4,22]. It was alsog. A. Represent the retinal layer of control rats. B. Represents the
ganglion cell death was detected by TUNEL (green), and the nuclei
Figure 2 Represent the mRNA expression of HMGB1, PLA2,
TNF-α, VEGF, ICAM-1 from the retinal tissue of control and
diabetic retinopathy rats.
Figure 3 Represent the western blot detecting the protein levels of A
the quantification of their corresponding band intensity from the ret
Table 3 PLA2 activity
Groups PLA2 activity (pmol/min/mg)
Control (non-diabetic) 14.7 ± 1.1
Diabetic (STZ) 55.9 ± 5.7*
Diabetic + AACOCF3 21.2 ± 2.4**
*Indicate the significance (p < 0.05) Diabetic Vs Control.
**Indicate the significance (p < 0.05) Diabetic Vs Diabetic + AACOCF3.
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tissues [5,23]. In this study, we demonstrated that HMGB-
1 could mediate endothelial cell death directly, while peri-
cyte death was indirectly mediated by HMGB-1-induced
cytotoxic activity of glial cells. HMGB-1 can also affect
endothelial cell activity. However, our findings suggest that
HMGB-1 plays an insignificant role in retina and choroidal
neovascularization.
Similarly, several isoforms of PLA2 have been identified
and localized in different structures of the eye [24]. They
have also been associated with the regulation of retinal. HMGB1, B. PLA2, C. IL-1β, D. TNF-α, E. VEGF, and F. ICAM-1 with
inal tissue of control and diabetic retinopathy rats.
Figure 4 Evaluation of PLA2 and COX proteins. A. Represent the protein expression of total protein cPLA2 and its phosphorylated form in
control and diabetic retinopathy rats and B. Represent the quantification of corresponding band intensity using image-J analysis. C. Represent the
protein expression of COX-1 and COX-2 in control and diabetic retinopathy rats. D. Represent the quantification of COX-1 and COX-2 band
intensity using image-J analysis.
Figure 5 Represent the HMGB1 (red) and DAPI (blue) staining of retinal layer of control and STZ-induced diabetic retinopathy rats.
The high expression of HMGB1 was noted in diabetic retinopathy. Scale bar = 50 μm.
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cell renewal [25] or to several retinal disease mechanisms
such as retinal edema formation in diabetic rats [26] or in
retinal angiogenesis in a rodent model of retinopathy of
prematurity [27]. Inhibition of PLA2, using either a iPLA2-
specific compound or cPLA2/iPLA2 non-selective com-
pound, dampened the glucose-induced elevation of PGE2
and VEGF both in BREC and BRPC. Furthermore, cPLA2
and iPLA2 siRNA transfection decreased VEGF-induced
BREC proliferation and BRPC loss, suggesting the import-
ance of cPLA2 as a positive regulator of VEGF-induced
retinal angiogenesis. This knock down experiment further
validates the results obtained with inhibitors, that may
otherwise be theoretically attributed, at least in part, to
nonspecific, off target effects [28].
The gene expression study had revealed that HMGB-1
and PLA2 affects endothelial cell activity. We found a
significant increased expression of HMGB-1 and PLA2,
similar pattern was also found in the expression of TNF-α,
VEGF and ICAM-1 in diabetic retinal cells. HMGB-1-
dependent increased expression of chemokines by glial
cells and endothelial cells can attract leukocytes to the
diabetic retina [29]. Increased expression of ICAM-1 can
facilitate increased adhesion of leukocytes to endothelia
[29]. It was shown that adherent leukocytes mediate endo-
thelial cell injury and death in the diabetic retina [29].
These data suggest that HMGB-1 and PLA2 could also in-
directly mediate endothelial cell death in patients suffering
from diabetic retinopathy. In addition, these results were
supported by the protein analysis of TNF-α, VEGF, IL-1β
and ICAM-1 in the diabetic retinal tissues.
Immunohistochemical analysis of human eyes has shown
constitutive expression of VEGFR-1, but not of VEGFR-2,
in samples from healthy controls, and up-regulation of
VEGFR-1 and new expression of VEGFR-2 in samples from
diabetic patients [30]. It is well known that VEGF directly
stimulates EC proliferation and migration, which leads to
the formation of new vessels; however, it seems also that, in
some circumstances, VEGF may act as an inhibitor of NV
by disrupting vascular smooth muscle cells function; specif-
ically, VEGF ablates PC coverage of nascent vascular
sprouts leading to vessel destabilization [31]. In the present
study, our result shows that high glucose or diabetes
increases VEGF but exert opposite effects on EC and PC
cell number are in accordance with this assumption.
Blood vessels become hemorrhagic and hyperdilated when
they lose pericytes, the vessel support cells [32]. The loss
of the pericytes is characteristic for the diabetic retina
[1,18]. The published literature demonstrated elevated
levels of HMGB-1 in diabetic retinas [20,21].
In this study, we have investigated the cellular mechan-
ism of action of HMGB-1 and PLA2 in diabetic retina. Our
findings indicate that retinal pericyte and endothelial injury
and death in diabetic retinopathy might be due to HMGB-1/PLA2 induced cytotoxic activity of glial cells as well as
the direct effect of HMGB-1 on endothelial cells. At the
same time, our data suggest that HMGB-1/PLA2 plays an
insignificant role in retinal and micro-neovascularization.
Thus, this study provides further insight into the research
on drug target or therapeutic role of HMGB-1/PLA2 in
diabetic retinopathy.
Competing interests
The authors declare that they have no competing interests to disclose
regarding the publication of this article.
Authors’ contributions
YG and XJ contributed equally to analyses the data and draft the manuscript,
participated in data management and cleaning. QSW, SHW, BKH and HYL
designed the study, directed its implementation and were responsible for
data management and cleaning, quality assurance and control. MNZ and
ZHL reviewed and revised the manuscript critically. All authors read and
approved the final manuscript.
Author details
1Department of Ophthalmology, Chinese PLA General Hospital, No. 28
Fuxing Road, Haidian District, Beijing 100853, China. 2Department of Health
Care, Headquarters Clinic of Chinese People’s Armed Police Force, Beijing,
China.
Received: 31 July 2014 Accepted: 15 August 2014
Published: 8 October 2014
References
1. Antonetti DA, Klein R, Gardner TW: Diabetic retinopathy. N Engl J Med
2012, 366:1227–1239.
2. International Diabetes Federation: IDF Diabetes Atlas. 6th edition. Brussels,
Belgium: International Diabetes Federation; 2013. http://www.idf.org/
diabetesatlas.
3. Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet 2010, 376:124–136.
4. Dvoriantchikova G, Hernandez E, Grant J, Santos AR, Yang H, Ivanov D: The
high-mobility group box-1 nuclear factor mediates retinal injury after is-
chemia reperfusion. Invest Ophthalmol Vis Sci 2011, 52:7187–7194.
5. van Beijnum JR, Buurman WA, Griffioen AW: Convergence and
amplification of toll-like receptor (TLR) and receptor for advanced
glycation end products (RAGE) signaling pathways via high mobility
group B1 (HMGB1). Angiogenesis 2008, 11:91–99.
6. Anfuso CD, Assero G, Lupo G, Nicotra A, Cannavo’ G, Strosznajder RP,
Rapisarda P, Pluta R, Alberghina M: Amyloid beta(1–42) and its beta
(25–35) fragment induce activation and membrane translocation of
cytosolic phospholipase A2 in bovine retina capillary pericytes.
Biochim Biophys Acta 2004, 1686:125–138.
7. Nicotra A, Lupo G, Giurdanella G, Anfuso CD, Ragusa N, Tirolo C, Marchetti
B, Alberghina M: MAPKs mediate the activation of cytosolic
phospholipase A2 by amyloid beta(25–35) peptide in bovine retina
pericytes. Biochim Biophys Acta 2005, 1733:172–186.
8. Singh NK, Hansen DE 3rd, Kundumani-Sridharan V, Rao GN: Both Kdr
and Flt1 play a vital role in hypoxia-induced Src-PLD1-PKCg-cPLA(2)
activation and retinal neovascularization. Blood 2013, 121:1911–1923.
9. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B: Vascular endothelial growth
factor (VEGF) – Part 1: In physiology and pathophysiology. Endokrynol Pol
2011, 62:444–455.
10. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee
M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy.
Diabetes 2002, 51:3107–3112.
11. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U,
Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for
inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004,
18:1450–1452.
12. Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, Poulaki
V, Semkova I, Kociok N: TNF alpha mediated apoptosis plays an important
role in the development of early diabetic retinopathy and long-term
histopathological alterations. Mol Vis 2009, 15:1418–1428.
Gong et al. Lipids in Health and Disease 2014, 13:156 Page 8 of 8
http://www.lipidworld.com/content/13/1/15613. Giurdanella G, Motta C, Muriana S, Arena V, Anfuso CD, Lupo G, Alberghina
M: Cytosolic and calcium-independent phospholipase A2 mediate glioma
enhanced proangiogenic activity of brain endothelial cells. Microvasc Res
2011, 81:1–17.
14. Lupo G, Anfuso CD, Ragusa N, Strosznajder RP, Walski M, Alberghina M:
t-Butyl hydroperoxide and oxidized low density lipoprotein enhance
phospholipid hydrolysis in lipopolysaccharide-stimulated retinal
pericytes. Biochim Biophys Acta 2001, 1531:143–155.
15. Gavrieli Y, Gavrieli Y, Ben-Sasson SA: Identification of programmed cell
death in situ via specific labeling of nuclear DNA fragmentation.
J Cell Biol 1992, 119:493–501.
16. Bucolo C, Leggio GM, Drago F, Salomone S: Eriodictyol prevents early
retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
Biochem Pharmacol 2012, 84:88–92.
17. Elanchezhian R, Palsamy P, Madson CJ, Lynch DW, Shinohara T: Age-related
cataracts: homocysteine coupled endoplasmic reticulum stress and
suppression of Nrf2-dependent antioxidant protection. Chem Biol Interact
2012, 200:1–10.
18. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD,
Ferris FL 3rd, Klein R: Retinopathy in diabetes. Diabetes Care 2004,
27(1):S84–S87.
19. Ferrara N: Vascular endothelial growth factor: basic science and clinical
progress. Endocr Rev 2004, 25:581–611.
20. El-Asrar AM, Missotten L, Geboes K: Expression of high-mobility groups
box-1/receptor for advanced glycation end products/osteopontin/early
growth response-1 pathway in proliferative vitreoretinal epiretinal
membranes. Mol Vis 2011, 17:508–518.
21. Abu El-Asrar AM, Nawaz MI, Kangave D, Abouammoh M, Mohammad G:
High-mobility group box-1 and endothelial cell angiogenic markers in
the vitreous from patients with proliferative diabetic retinopathy.
MediatoInflamm 2012, 2012:697489.
22. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ: HMGB1 and RAGE in
inflammation and cancer. Annu Rev Immunol 2010, 28:367–388.
23. Lin Q, Yang XP, Fang D, Ren X, Zhou H, Fang J, Liu X, Zhou S, Wen F, Yao X,
Wang JM, Su SB: High-mobility group box-1 mediates toll-like receptor
4-dependent angiogenesis. Arterioscler Thromb Vasc Biol 2011, 31:1024–1032.
24. Wang J, Kolko M: Phospholipases A2 in ocular homeostasis and diseases.
Biochimie 2010, 92:611–619.
25. Kolko M, Wang J, Zhan C, Poulsen KA, Prause JU, Nissen MH, Heegaard S,
Bazan NG: Identification of intracellular phospholipases A2 in the human
eye: involvement in phagocytosis of photoreceptor outer segments.
Invest Ophthalmol Vis Sci 2007, 48:1401–1409.
26. Pannicke T, Iandiev I, Wurm A, Uckermann O, vom Hagen F, Reichenbach A,
Wiedemann P, Hammes HP, Bringmann A: Diabetes alters osmotic
swelling characteristics and membrane conductance of glial cells in rat
retina. Diabetes 2006, 55:633–639.
27. Barnett JM, McCollum GW, Penn JS: Role of cytosolic phospholipase A(2)
in retinal neovascularization. Invest Ophthalmol Vis Sci 2009, 51:1136–1142.
28. Salomone S, Waeber C: Selectivity and specificity of sphingosine-1-
phosphate receptor ligands: caveats and critical thinking in
characterizing receptormediated effects. Front Pharmacol 2011, 2:9.
29. Noda K, Nakao S, Ishida S, Ishibashi T: Leukocyte adhesion molecules in
diabetic retinopathy. J Ophthalmol 2012, 2012:279037.
30. Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF,
Schlingemann RO: Altered expression patterns of VEGF receptors in
human diabetic retina and in experimental VEGF-induced retinopathy in
monkey. Invest Ophthalmol Vis Sci 2002, 43:849–857.
31. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J,
Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA: A role for
VEGF as a negative regulator of pericyte function and vessel maturation.
Nature 2008, 456:809–813.
32. Bergers G, Song S: The role of pericytes in blood-vessel formation and
maintenance. Neuro Oncol 2005, 7:452–464.
doi:10.1186/1476-511X-13-156
Cite this article as: Gong et al.: The involvement of high mobility group
1 cytokine and phospholipases A2 in diabetic retinopathy. Lipids in
Health and Disease 2014 13:156.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
